Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 6/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30670211 | 1.00 | LMNA (0.55) | LMNAKMT2AJUNNFKB1NFKB2 | |
| SCHEMBL22538561 | 0.80 | GABRG2 (0.38) | LMNAKMT2AGABRG2GABRB3GABRA1 | |
| SCHEMBL30371718 | 0.80 | GABRG2 (0.38) | LMNAKMT2AGABRG2GABRB3GABRA1 | |
| SCHEMBL29552833 | 0.79 | MAPK1 (0.47) | LMNAKMT2AJUNNFKB1NFKB2 | |
| SCHEMBL474101 | 0.79 | MAPK1 (0.47) | LMNAKMT2AJUNNFKB1NFKB2 | |
| SCHEMBL14753354 | 0.79 | LMNA (0.49) | LMNAKMT2AJUNNFKB1NFKB2 | |
| SCHEMBL28901905 | 0.79 | GABRG2 (0.38) | LMNAKMT2AGABRG2GABRB3GABRA1 | |
| SCHEMBL22874342 | 0.76 | JUN (0.46) | LMNAKMT2AJUNNFKB1NFKB2 | |
| SCHEMBL26657700 | 0.75 | ALDH1A1 (0.44) | LMNAKMT2AJUNNFKB1NFKB2 | |
| SCHEMBL2473041 | 0.75 | CYP1A2 (0.53) | LMNAKMT2AGABRA2GABRB2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| WO-2025108406-A1 | HETEROCYCLIC COMPOUND OF BIFUNCTIONAL CHIMERA FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR, AND USE THEREOF | 广东东阳光药业股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| WO-2025108404-A1 | HETEROCYCLIC COMPOUND OF BIFUNCTIONAL CHIMERA FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND USE THEREOF | 广东东阳光药业股份有限公司 | 2025-05-30 | — | — | WO | disclosed |
| CN-120025333-A | Heterocyclic compound of bifunctional chimera for targeting and degrading androgen receptor and application thereof | 广东东阳光药业股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-120025326-A | Heterocyclic compound of bifunctional chimera for targeting and degrading androgen receptor and application thereof | 广东东阳光药业股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| WO-2025097061-A1 | ApoB DEGRADING COMPOUNDS AND USES THEREOF | AVILAR THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025081092-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025011623-A1 | CYANOQUINOLINE-TARGETING PROTEIN DEGRADATION MOLECULE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海壹迪生物技术有限公司 | 2025-01-16 | — | — | WO | disclosed |
| WO-2024098039-A2 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-3795570-A1 | SUBSTITUTED QUINOLINE-8-CARBONITRILE DERIVATIVES HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | Accutar Biotechnology Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
| CN-112010858-A | BTK inhibitor, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2020-12-01 | — | — | CN | disclosed |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10836749-B1 | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-11-17 | — | — | US | disclosed |
| EP-3660004-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas Operations, Inc. (US) | 2020-06-03 | — | — | EP | disclosed |
| WO-2018071606-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | LMNA 4818/4885KMT2A 1474/4885JUN 4270/4885 |
| US-20210040044-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | LMNA 2932/4885KMT2A 1478/4885JUN 4245/4885 |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | LMNA 2916/4885KMT2A 1463/4885JUN 4226/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | LMNA 2932/4885KMT2A 1478/4885JUN 4245/4885 |
| US-10844021-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | LMNA 2932/4885KMT2A 1478/4885JUN 4245/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | LMNA 3350/4885KMT2A 4453/4885JUN 3596/4885 |
| US-20210038607-A1 | OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC5, HDAC3 | LMNA 3656/4885KMT2A 538/4885JUN 4397/4885 |
| US-10836749-B1 | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | AR, NR5A1, ESRRA | LMNA 1600/4885KMT2A 1654/4885JUN 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.